{"id":848999,"date":"2025-05-08T08:08:33","date_gmt":"2025-05-08T12:08:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/"},"modified":"2025-05-08T08:08:33","modified_gmt":"2025-05-08T12:08:33","slug":"merus-to-present-at-bofa-securities-2025-health-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/","title":{"rendered":"Merus to Present at BofA Securities 2025 Health Care Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">UTRECHT, The Netherlands and CAMBRIDGE, Mass., May  08, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXTCtha317iZxMQQ0f8O1VDHzGlMoiUkc8mzrlfS4LkRk0lkrfSzXXlVjqKOBEOvH1W_SKS6EhSbnSb0brgEsw==\" rel=\"nofollow\" target=\"_blank\">Merus N.V<\/a>. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics<sup>\u00ae<\/sup> and Triclonics<sup>\u00ae<\/sup>), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT\/11:40 a.m. ET.<\/p>\n<p>The webcast of the presentation will be contemporaneously available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Lwaru_CtRXbzqjXIzW3E_P52e0uSzJi1UoT-xA2DFF8oDKDA0nrLr8uLzn3CfOIBmdylLxfbhZfuXjTQNYJahxocCFIagLjxv2Wl_43jr-E=\" rel=\"nofollow\" target=\"_blank\">Investors page<\/a> of the Company&#8217;s website. The archived presentation will also be available there for a limited time after the event.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About Merus<\/strong><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXTCtha317iZxMQQ0f8O1bQl1dTi8mPTB3_Ox7GojRdqHqiIwpiZR1csaKCuRT4odPyY-dZTLUWyYpsId-PkmA==\" rel=\"nofollow\" target=\"_blank\">Merus<\/a> is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UsjZrHoiRrl6YiCSTGHG4Qd5_KBGU-98IUj_4wp2Z4XUihawXj1-L-_OiXLjqNWv7TSeXXbSyz2CDXsMFaHq94J8DOR8TSF5cx4rBZv0MOt_fFqpJc7U3jn0cnwIxLvD\" rel=\"nofollow\" target=\"_blank\">Multiclonics<sup>\u00ae<\/sup><\/a>. Multiclonics<sup>\u00ae<\/sup> are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXTCtha317iZxMQQ0f8O1cbM0p7_PQq-FiMO_2DOR-BPDuInQ-hAyfVKHHqFAlHq3bVqc_-v3TOXM-e6SxeU6A==\" rel=\"nofollow\" target=\"_blank\">Merus\u2019 website<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gFks_0hAOlxnReNEj0UeFrnB0or0xP48zsRsdl7njj8izOnMBqfnllDF29FsarqtTyxxUsDj2bCYYehMOPlVrheWgOBJNcL3q-_3dtxLZwQ=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>Multiclonics<sup>\u00ae<\/sup>, Biclonics<sup>\u00ae<\/sup> and Triclonics<sup>\u00ae<\/sup> are registered trademarks of Merus N.V.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjkyMGFlNDctM2I0ZC00OWIzLWI0OTktNDVkNGZmMmEyNGZhLTEwMzE4NTktMjAyNS0wNS0wOC1lbg==\/tiny\/Merus-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor and Media Inquiries:\r\nSherri Spear\r\nMerus N.V.\r\nSVP Investor Relations and Strategic Communications\r\n617-821-3246\r\ns.spear@merus.nl\r\n\r\nKathleen Farren\r\nMerus N.V.\r\nDirector IR\/Corp Comms\r\n617-230-4165\r\nk.farren@merus.nl<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT\/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Merus to Present at BofA Securities 2025 Health Care Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-848999","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT\/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using &hellip; Continue reading &quot;Merus to Present at BofA Securities 2025 Health Care Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T12:08:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Merus to Present at BofA Securities 2025 Health Care Conference\",\"datePublished\":\"2025-05-08T12:08:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/\"},\"wordCount\":178,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/\",\"name\":\"Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\",\"datePublished\":\"2025-05-08T12:08:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merus-to-present-at-bofa-securities-2025-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merus to Present at BofA Securities 2025 Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk","og_description":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) &#8212; Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics\u00ae and Triclonics\u00ae), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT\/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company&#8217;s website. The archived presentation will also be available there for a limited time after the event. About Merus Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics\u00ae. Multiclonics\u00ae are manufactured using &hellip; Continue reading \"Merus to Present at BofA Securities 2025 Health Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-08T12:08:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Merus to Present at BofA Securities 2025 Health Care Conference","datePublished":"2025-05-08T12:08:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/"},"wordCount":178,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/","name":"Merus to Present at BofA Securities 2025 Health Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=","datePublished":"2025-05-08T12:08:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjkyMCM2OTI4Mjk5IzIwMjAyODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merus-to-present-at-bofa-securities-2025-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Merus to Present at BofA Securities 2025 Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=848999"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=848999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=848999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=848999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}